Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
暂无分享,去创建一个
M. Sprangers | M. Chesney | F. de Wolf | S. Danner | H. Sprenger | J. Lange | R. Hoetelmans | J. Lange | M A Chesney | S A Danner | F de Wolf | F. Wolf | D. Burger | P T Nieuwkerk | M A Sprangers | D M Burger | R M Hoetelmans | P W Hugen | M E van Der Ende | M M Schneider | G Schrey | P L Meenhorst | H G Sprenger | R H Kauffmann | M Jambroes | J M Lange | M. Jambroes | P. Meenhorst | P. Nieuwkerk | R. Kauffmann | M. Ende | G. Schrey | P. Hugen | M. M. Schneider | M. Van Der Ende | Margriet M. E. Schneider
[1] J. Montaner,et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. , 1998, The Journal of infectious diseases.
[2] J. Rabkin,et al. Adherence: a necessity for successful HIV combination therapy. , 1999, AIDS.
[3] D. Richman,et al. Predictors of Self‐Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral Regimens , 2000, Journal of acquired immune deficiency syndromes.
[4] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[5] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[6] C. Rand,et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. , 1999, Medical care.
[7] W. Dolmans,et al. Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy , 1998, Antiviral therapy.
[8] M A Fischl,et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.
[9] F. Brun-Vézinet,et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.
[10] H. Schuitemaker,et al. Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study , 2000, AIDS.
[11] M A Wainberg,et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use , 2000, AIDS.
[12] ศิริลักษณ์ อนนันต์ณัฐศิริ,et al. Antiretroviral Therapy for HIV Infection in 1998 , 1998 .
[13] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[14] Y. Hekster,et al. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. , 1999 .
[15] V. Soriano,et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. , 1999, AIDS.
[16] D Johnson,et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.
[17] Y. Hekster,et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[18] J. Dieleman,et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. , 1999, AIDS.
[19] J W Mulder,et al. The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy , 1998, AIDS.
[20] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[21] J. Kahn,et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.
[22] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[23] J. Beijnen,et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[24] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[25] S. Paulous,et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. , 1999, AIDS.
[26] C. Sabin,et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. , 1999, AIDS.
[27] J. Moatti,et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment , 2000, AIDS.
[28] V. Calvez,et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.
[29] J. Beijnen,et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.